Can early therapy reduce inflammation?

Current Opinion in HIV and AIDS

Volumn 9, Issue 1, 2014, Pages 72-79

  Sandler, Netanya G ^a   Sereti, Irini ^b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

biomarkers; HIV; inflammation; monocyte activation; morbidity; T cell activation

Indexed keywords

ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTIVE IMMUNITY; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC INFLAMMATION; COMPARATIVE STUDY; DISEASE CONTROL; DISEASE COURSE; DRUG EXPOSURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEROCONVERSION; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE ACTIVATION; VIRUS REPLICATION;

ANTI-HIV AGENTS; BIOLOGICAL MARKERS; HIV INFECTIONS; HUMANS; INFLAMMATION; LYMPHOCYTE ACTIVATION; MONOCYTES; T-LYMPHOCYTES;

EID: 84892372311     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000020     Document Type: Review

References (100)

1. Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011; 53: 1120-1126
2. Hasse B, Ledergerber B, Furrer H, et al. Morbidity and aging in HIV-infected persons: The swiss HIV cohort study. Clin Infect Dis 2011; 53: 1130-1139
3. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4 count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-2296
4. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5: E203
5. Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203: 780-790
6. Duprez DA, Neuhaus J, Kuller LH, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One 2012; 7: E44454
7. Janeway CA Jr, Travers P, Walport M, et al. The front line of host defense. In: Immunobiology: The immune system in health and disease. 5th ed. New York: Garland Science; 2001; http: //www.ncbi.nlm.nih.gov/books/NBK27105/. [Accessed 18 August 2013
8. Douek DC, Picker LJ, Koup RA. T cell dynamics in HIV-1 infection. Annu Rev Immunol 2003; 21: 265-304
9. Kulpa DA, Lawani M, Cooper A, et al. PD-1 coinhibitory signals: The link between pathogenesis and protection. Semin Immunol 2013; 30 March 2013. [Epub ahead of print
10. Stacey AR, Norris PJ, Qin L, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 2009; 83: 3719-3733
11. Liovat AS, Rey-Cuille MA, Lecuroux C, et al. Acute plasma biomarkers of T cell activation set-point levels and of disease progression in HIV-1 infection. PLoS One 2013; 7: E46143
12. Fahey JL, Taylor JM, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990; 322: 166-172
13. Bosinger SE, Li Q, Gordon SN, et al. Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J Clin Invest 2009; 119: 3556-3572
14. Jacquelin B, Mayau V, Targat B, et al. Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J Clin Invest 2009; 119: 3544-3555
15. Sandler NG, Zhu R, Estes JD, et al. Blockade of Type I interferon during acute SIV infection results in accelerated progression to AIDS and death. 20th conference on retroviruses and opportunistic infections, Atlanta, GA, 3-6 March 2013: Abstract 77
16. Boulware DR, Hullsiek KH, Puronen CE, et al. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis 2011; 203: 1637-1646
17. Burdo TH, Lentz MR, Autissier P, et al. Soluble CD163 made by monocyte/ macrophages is a novel marker of HIV activity in early and chronic infection prior to and after antiretroviral therapy. J Infect Dis 2011; 204: 154-163
18. Musselwhite LW, Sheikh V, Norton TD, et al. Markers of endothelial dysfunction, coagulation and tissue fibrosis independently predict venous thromboembolism in HIV. AIDS 2011; 25: 787-795
19. Tilling R, Kinloch S, Goh LE, et al. Parallel decline of CD8/CD38 T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection. AIDS 2002; 16: 589-596
20. Deeks SG, Kitchen CM, Liu L, et al. Immune activation set point during early HIV infection predicts subsequent CD4 T-cell changes independent of viral load. Blood 2004; 104: 942-947
21. Gay CL, Mayo AJ, Mfalila CK, et al. Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection. AIDS 2011; 25: 941-949
22. Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179: 859-870
23. Hazenberg MD, Otto SA, van Benthem BH, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003; 17: 1881-1888
24. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4 T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187: 1534-1543
25. Zhang X, Hunt PW, Hammer SM, et al. Immune activation while on potent antiretroviral therapy can predict subsequent CD4 T-cell increases through 15 years of treatment. HIV Clin Trials 2013; 14: 61-67
26. Erlandson KM, Allshouse AA, Jankowski CM, et al. Association of functional impairment with inflammation and immune activation in HIV type 1-infected adults receiving effective antiretroviral therapy. J Infect Dis 2013; 208: 249-259
27. Hunt PW, Cao HL, Muzoora C, et al. Impact of CD8 T-cell activation on CD4 T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS 2011; 25: 2123-2131
28. Catalfamo M, Di Mascio M, Hu Z, et al. HIV infection-Associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells. Proc Natl Acad Sci U S A 2008; 105: 19851-19856
29. Lee PI, Ciccone EJ, Read SW, et al. Evidence for translocation of microbial products in patients with idiopathic CD4 lymphocytopenia. J Infect Dis 2009; 199: 1664-1670
30. Smith MZ, Bastidas S, Karrer U, Oxenius A. Impact of antigen specificity on CD4Tcell activation inchronicHIV-1 infection.BMCInfect Dis2013;13: 100
31. Wilson JD, OggGS, AllenRL, et al. Oligoclonal expansions ofCD8() T cells in chronic HIV infection are antigen specific. J Exp Med 1998; 188: 785-790
32. Cubas RA, Mudd JC, Savoye AL, et al. Inadequate T follicular cell help impairs B cell immunity during HIV infection. Nat Med 2013; 19: 494-499
33. Aghaeepour N, Chattopadhyay PK, Ganesan A, et al. Early immunologic correlates of HIV protection can be identified from computational analysis of complex multivariate T-cell flow cytometry assays. Bioinformatics 2012; 28: 1009-1016
34. Funderburg NT, Mayne E, Sieg SF, et al. Increased tissue factor expression on circulating monocytes in chronic HIV infection: Relationship to in vivo coagulation and immune activation. Blood 2010; 115: 161-167
35. Hearps AC, Maisa A, Cheng WJ, et al. HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy. AIDS 2012; 26: 843-853
36. Martin GE, Gouillou M, Hearps AC, et al. Age-Associated changes in monocyte and innate immune activation markers occur more rapidly in HIV infected women. PLoS One 2013; 8: E55279
37. Kelesidis T, Kendall MA, Yang OO, et al. Biomarkers of microbial translocation and macrophage activation: Association with progression of subclinical atherosclerosis in HIV-1 infection. J Infect Dis 2012; 206: 1558-1567
38. Pereyra F, Lo J, Triant VA, et al. Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. AIDS 2012; 26: 2409-2412
39. Lyons JL, Uno H, Ancuta P, et al. Plasma sCD14 is a biomarker associated with impaired neurocognitive test performance in attention and learning domains in HIV infection. J Acquir Immune Defic Syndr 2011; 57: 371-379
40. Hsue PY, Scherzer R, Hunt PW, et al. Carotid intima-media thickness progression in HIV-infected adults occurs preferentially at the carotid bifurcation and is predicted by inflammation. J Am Heart Assoc 2012; 1: 1-13
41. Baker J, Huppler Hullsiek K, Singh A, et al. Monocyte activation, but not T-cell activation, predicts progression of coronary artery calcium in a contemporary HIV cohort. 20th conference on retroviruses and opportunistic infections, Atlanta, GA, 3-6 March 2013: Abstract 66LB
42. Anthony KB, Yoder C, Metcalf JA, et al. Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover. J Acquir Immune Defic Syndr 2003; 33: 125-133
43. Lederman MM, Calabrese L, Funderburg NT, et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis 2011; 204: 1217-1226
44. Rajasuriar R, Booth D, Solomon A, et al. Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: The role of interleukin 7 and interleukin 7 receptor alpha and microbial translocation. J Infect Dis 2010; 202: 1254-1264
45. French MA, King MS, Tschampa JM, et al. Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4 T cells. J Infect Dis 2009; 200: 1212-1215
46. Wilson EM, Sereti I. Immune restoration after antiretroviral therapy: The pitfalls of hasty or incomplete repairs. Immunol Rev 2013; 254: 343-354
47. Sandler NG, Douek DC. Microbial translocation in HIV infection: Causes, consequences and treatment opportunities. Nat Rev Microbiol 2012; 10: 655-666
48. Hunt PW. HIV and inflammation: Mechanisms and consequences. Curr HIV/ AIDS Rep 2012; 9: 139-147
49. Tenorio A, Zheng E, Bosch R, et al. Soluble markers of inflammation and coagulation, but not T-cell activation, predict non-AIDS-defining events during suppressive ART. 20th conference on retroviruses and opportunistic infections, Atlanta, GA, 3-6 March 2013: Abstract 790
50. Hunt PW, Sinclair E, Rodriguez B, et al. Gut epithelial barrier dysfunction, inflammation, and coagulation predict higher mortality during treated HIV/ AIDS. 19th conference on retroviruses and opportunistic infections, Seattle, WA, 5-8 March 2012: Abstract #278
51. Hurley A, Smith M, Karpova T, et al. Enhanced effector function of CD8 T cells from healthy controls and HIV-infected patients occurs through thrombin activation of protease-Activated receptor 1. J Infect Dis 2013; 207: 638-650
52. Gutierrez C, Diaz L, Vallejo A, et al. Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: Effect on T cells latently infected. PLoS One 2011; 6: E27864
53. Wilkin TJ, Lalama CM, McKinnon J, et al. A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4() T-cell recovery despite sustained virologic suppression: ACTG A5256. J Infect Dis 2012; 206: 534-542
54. Hunt PW, Shulman NS, Hayes TL, et al. The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4 T-cell recovery: A randomized trial. Blood 2013; 121: 4635-4646
55. Buzon MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of highly active antiretroviral therapy (HAART)-suppressed subjects. Nat Med 2010; 16: 460-465
56. Massanella M, Negredo E, Puig J, et al. Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery. AIDS 2012; 26: 2285-2293
57. Lichtenstein KA, Armon C, Nagabhushanam V, et al. A pilot study to assess inflammatory biomarker changes when raltegravir is added for 48 weeks to a virologically suppressive HAART regimen in HIV-1-infected patients with limited immunological responses. Antivir Ther 2012; 17: 1301-1309
58. Yukl SA, Shergill AK, McQuaid K, et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS 2010; 24: 2451-2460
59. Hatano H, Scherzer R, Wu Y, et al. A randomized controlled trial assessing the effects of raltegravir intensification on endothelial function in treated HIV infection. J Acquir Immune Defic Syndr 2012; 61: 317-325
60. Hatano H, Strain MC, Scherzer R, Bacchetti P, et al. Increase in 2-LTR circles and decrease in D-dimer after raltegravir intensification in treated HIVinfected patients: A randomized, placebo-controlled trial. J Infect Dis 2013; 208: 1436-1442
61. Silva EF, Charreau I, Gourmel B, et al. Decreases in inflammatory and coagulation biomarkers levels in HIV-infected patients switching from enfuvirtide to raltegravir: ANRS 138 substudy. J Infect Dis 2013; 208: 892-897. [Epub ahead of print
62. Martinez E, D'Albuquerque PM, Llibre JM, et al. Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS 2012; 26: 2315-2326
63. Lake J, McComsey G, Hulgan T, et al. Soluble CD14 declines in virologically suppressed women switching from PI or NNRTI to raltegravir: The Women, Integrase, and Fat Accumulation Trial. 20th conference on retroviruses and opportunistic infections, Atlanta, GA, 3-6 March 2013: Abstract #794
64. Masia M, Martinez E, Padilla S, et al. Endothelial function in HIV-infected patients switching from a boosted protease inhibitor-based regimen to raltegravir: A substudy of the SPIRAL study. J Antimicrob Chemother 2013; 68: 409-413
65. Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: A: D study: A multicohort collaboration. Lancet 2008; 371: 1417-1426
66. Costagliola D, Lang S, Mary-Krause M, Boccara F. Abacavir and cardiovascular risk: Reviewing the evidence. Curr HIV/AIDS Rep 2010; 7: 127-133
67. Ribaudo HJ, Benson CA, Zheng Y, et al. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: Short and long-Term results from ACTG A5001/ALLRT. Clin Infect Dis 2011; 52: 929-940
68. McComsey GA, Kitch D, Daar ES, et al. Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. AIDS 2012; 26: 1371-1385
69. Martinez E, d'Albuquerque PM, Perez I, et al. Abacavir/lamivudine versus tenofovir/emtricitabine in virologically suppressed patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS Res Hum Retroviruses 2013; 29: 235-241
70. Campo R, DeJesus E, Bredeek UF, et al. SWIFT: Prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen. Clin Infect Dis 2013; 56: 1637-1645
71. Mocroft A, Furrer HJ, Miro JM, et al. The incidence of AIDS-defining illnesses at a current CD4 count >-200 cells/mul in the postcombination antiretroviral therapy era. Clin Infect Dis 2013; 57: 1038-1047
72. Rodger AJ, Lodwick R, Schechter M, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS 2013; 27: 973-979
73. Lodwick RK, Sabin CA, Porter K, et al. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: A pooled cohort observational study. Lancet 2010; 376: 340-345
74. Lucero C, Torres B, Leon A, et al. Rate and predictors of non-AIDS events in a cohort of HIV-infected patients with a CD4 T cell count above 500 cells/mm3. AIDS Res Hum Retroviruses 2013; 29: 1161-1167
75. Ho JE, Scherzer R, Hecht FM, et al. The association of CD4 T-cell counts and cardiovascular risk in treated HIV disease. AIDS 2012; 26: 1115-1120
76. van Lelyveld SF, Gras L, Kesselring A, et al. Long-Term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort. AIDS 2012; 26: 465-474
77. Grant PM, Kitch D, McComsey GA, et al. Low baseline CD4 count is associated with greater bone mineral density loss after ART initiation. Clin Infect Dis 2013; 57: 1483-1488. [Epub ahead of print
78. Le T, Wright EJ, Smith DM, et al. Enhanced CD4 T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med 2013; 368: 218-230
79. Hoen B, Cooper DA, Lampe FC, et al. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005. Clin Infect Dis 2007; 45: 381-390
80. Chevalier MF, Petitjean G, Dunyach-Remy C, et al. The Th17/Treg ratio, IL-1RA and sCD14 levels in primary HIV infection predict the T-cell activation set point in the absence of systemic microbial translocation. PLoS Pathog 2013; 9: E1003453
81. Vinikoor MJ, Cope A, Gay CL, et al. Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation. J Acquir Immune Defic Syndr 2013; 62: 505-508
82. Jain V, Hartogensis W, Bacchetti P, et al. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis 2013; 208: 1202-1211
83. Ananworanich J, Schuetz A, Vandergeeten C, et al. Impact of multitargeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One 2012; 7: E33948
84. Burdo TH, Lo J, Abbara S, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis 2011; 204: 1227-1236
85. Burdo TH, Weiffenbach A, Woods SP, et al. Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection. AIDS 2013; 27: 1387-1395
86. Saez-Cirion A, Bacchus C, Hocqueloux L, et al. Posttreatment HIV-1 controllers with a long-Term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013; 9: E1003211
87. Goujard C, Girault I, Rouzioux C, et al. HIV-1 control after transient antiretroviral treatment initiated in primary infection: Role of patient characteristics and effect of therapy. Antivir Ther 2012; 17: 1001-1009
88. Longenecker CT, Jiang Y, Yun CH, et al. Perivascular fat, inflammation, and cardiovascular risk in HIV-infected patients on antiretroviral therapy. Int J Cardiol 2013; 168: 4039-4045
89. Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: A position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation 2010; 121: 2694-2701
90. Gao XR, Adhikari CM, Peng LY, et al. Efficacy of different doses of aspirin in decreasing blood levels of inflammatory markers in patients with cardiovascular metabolic syndrome. J Pharm Pharmacol 2009; 61: 1505-1510
91. Ikonomidis I, Andreotti F, Economou E, et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999; 100: 793-798
92. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial. Lancet 2009; 373: 1175-1182
93. Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and meta-Analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011; 108: 1362-1370
94. Gori A, Rizzardini G, Van 't Land B, et al. Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: Results of the 'COPA' pilot randomized trial. Mucosal Immunol 2011; 4: 554-563
95. PettersenFO, TorheimEA, DahmAE, et al.Anexploratorytrialofcyclooxygenase type 2 inhibitor in HIV-1 infection: Downregulated immune activation and improved T cell-dependent vaccine responses. J Virol 2011; 85: 6557-6566
96. Hunt PW, Martin JN, Sinclair E, et al. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4 T cell recovery on antiretroviral therapy. J Infect Dis 2011; 203: 1474-1483
97. SandlerNG, DouekDC. Microbial translocation inHIVinfection: Causes, consequences and treatment opportunities. Nat Rev Microbiol 2012; 10: 655-666
98. Taiwo B, Barcena L, Tressler R. Understanding and controlling chronic immune activation in the HIV-infected patients suppressed on combination antiretroviral therapy. Curr HIV/AIDS Rep 2013; 10: 21-32
99. McComsey GA, Jiang Y, Debanne S, et al. Effect of statins on immune activation and inflammation in HIV subjects on ART: A randomized placebo controlled trial. 20th conference on retroviruses and opportunistic infections, Atlanta, GA, 3-6 March 2013. Abstract 186B
100. Lesko CR, Cole SR, Zinski A, et al. A Systematic review and meta-regression of temporal trends in adult CD4 cell count at presentation to HIV care, 1992-2011. Clin Infect Dis 2013; 57: 1027-1037